share_log

個別銘柄のひと口情報

Individual stock information.

Kabushiki Shimbun ·  Mar 27 07:41

Oncolis B<4588.T>

The patent regarding the administration method of the tumor lysis adenovirus "OBP-301" that the company applied for has been granted patent approval in Japan. The patent expires in May 2040. There are plans to apply for approval for "OBP-301" as a regenerative medical product for esophageal cancer within this December. The stock price experienced a rise in the morning before losing value.

Basis<4068.T>

A significant continuation of the rise updated the high price last year. Starting from June 30th and December 31st each year, a shareholder benefit system will be introduced for shareholders holding 200 shares or more recorded on the shareholder...

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 384

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.